Compare Amgen, Inc. (AMGN) vs Deutsche Bank AG (DB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Deutsche Bank AG — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Deutsche Bank AG trades at $35.75 (market cap $68.30B). The key difference: Amgen, Inc. is far larger — about 2.9× Deutsche Bank AG's market cap, and Deutsche Bank AG pays the higher dividend (3.25%). Which is the better fit depends on your goals.
| AMGN | DB | |
|---|---|---|
Market Cap | $196.12B | $68.30B |
Sector | Health | Financials |
52-Week High | $388.16 | $40.33 |
52-Week Low | $271.18 | $28.37 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Deutsche Bank (DB) trades at $35.77, up 1.05% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamental momentum with Q1 2026 EPS beating expectations at $1.24 versus $1.15, and net income margin improving to 21.98% in 2025. Recent news includes expansion into Saudi Arabia and a dividend of $1.00 payable in June 2026, reflecting strategic growth initiatives.
Outlook is cautiously optimistic given low P/E of 9.94 and P/B of 0.77, suggesting undervaluation, but risks include volatile cash flows with a net outflow of $33.10B in 2024 and mixed analyst sentiment with only 21% buy ratings. Investors should weigh earnings consistency against macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
